Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Tibsovo FDA Approved, with Azacitidine, for Newly Diagnosed Patients with Acute Myeloid Leukemia and IDH1 Mutation

June 2022 Vol 8 No 3

In May 2022, the FDA approved oral Tibsovo (ivosidenib; from Servier Pharmaceuticals), for use with intravenous or subcutaneous azacitidine, for the treatment of newly diagnosed acute myeloid leukemia (AML) and a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients aged 75 years or older, or patients with other medical conditions that prevent the use of initial intensive chemotherapy.

This new indication was approved based on a clinical trial of 146 patients with newly diagnosed AML and IDH1 mutation. The patients were divided into 2 groups: 72 patients received Tibsovo plus azacitidine and 74 patients received placebo plus azacitidine until disease progression, unacceptable side effects, or undergoing stem-cell transplant.

The average overall survival was 2 years in the Tibsovo and azacitidine group compared with only 7.9 months in the placebo plus azacitidine group. After 24 weeks, almost half (47%) of the patients who received Tibsovo plus azacitidine had a complete response (no sign of cancer) to treatment compared with only 15% of those who received placebo plus azacitidine. The average length of complete remission was not reached in the Tibsovo arm (meaning patients are still responding to the treatment) compared with 11.2 months in the placebo arm.

The most common side effects reported with Tibsovo plus azacitidine or alone are diarrhea, fatigue, edema, nausea, vomiting, decreased appetite, leukocytosis, arthralgia, dyspnea, abdominal pain, mucositis, rash, differentiation syndrome (which may be life-threatening), and myalgia.

Treatment with Tibsovo plus azacitidine is recommended for a minimum of 6 months in patients who can tolerate the treatment or those whose cancer does not progress, to allow time for appropriate clinical response.

Recommended For You